drugset / Trial / NCT07232589

A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)

NCT07232589

Phase 1 Completed 26 enrolled Merck Sharp & Dohme LLC
Non-randomizedSequentialOpen-labelBasic science

Summary

The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called diltiazem.

Timeline

Start
2025-12-08
Primary completion
2026-05-04
Completion
2026-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Diltiazem Small molecule Oral
Subject Nemtabrutinib Other / unclassified Oral

Indications

No indication recorded.